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An effective response to the COVID-19
pandemic relies on integration of many
different types of data available about
SARS-CoV-2 and related viruses. KG-
COVID-19 is a framework for producing
knowledge graphs that can be
customized for downstream applications
including machine learning tasks,
hypothesis-based querying, and
browsable user interface to enable
researchers to explore COVID-19 data
and discover relationships.
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Integrated, up-to-date data about SARS-CoV-2 and COVID-19 is crucial for the ongoing response to the
COVID-19 pandemic by the biomedical research community. While rich biological knowledge exists for
SARS-CoV-2 and related viruses (SARS-CoV, MERS-CoV), integrating this knowledge is difficult and time-
consuming, since much of it is in siloed databases or in textual format. Furthermore, the data required by
the research community vary drastically for different tasks; the optimal data for a machine learning task,
for example, is much different from the data used to populate a browsable user interface for clinicians. To
address these challenges, we created KG-COVID-19, a flexible framework that ingests and integrates hetero-
geneous biomedical data to produce knowledge graphs (KGs), and applied it to create a KG for COVID-19
response. This KG framework also can be applied to other problems in which siloed biomedical data must
be quickly integrated for different research applications, including future pandemics.
INTRODUCTION
Although most coronaviruses typically cause common-cold
symptoms in humans, three betacoronaviruses have emerged
in the past few decades that can cause a range of serious man-
ifestations, including pneumonia and death: the severe acute
respiratory syndrome (SARS) coronavirus (SARS-CoV-1), the
Middle East respiratory syndrome coronavirus (MERS-CoV),
and the novel betacoronavirus that emerged in late 2019, subse-
quently named SARS-CoV-2, the agent of the disease COVID-
19.1 The rapid spread of SARS-CoV-2 has led to a global
pandemic.
THE BIGGER PICTURE An effective response to the COVID-19 pandemic relies on integration of many
different types of data available about SARS-CoV-2 and related viruses. KG-COVID-19 is a framework for
producing knowledge graphs that can be customized for downstream applications including machine
learning tasks, hypothesis-based querying, and browsable user interface to enable researchers to explore
COVID-19 data and discover relationships.
Development/Pre-production: Data science output has been
rolled out/validated across multiple domains/problems
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COVID-19 is a complex disease involving many biological pro-
cesses and pathways, each of which involves many genes. Initial
symptoms of COVID-19 typically include fever, cough, fatigue,
anorexia, anosmia, myalgia, and diarrhea. In some patients, se-
vere illness ensues roughly 1 week after the initial onset of
symptoms, and can present with rapidly progressive respiratory
failure.2 In addition to the symptoms highlighted, COVID-19 in-
fections can lead to secondary health problems, such as blood
clots,3 tissue necrosis, organ damage, and, in some cases, car-
diac failure. Given that the research community is still learning
about COVID-19, understanding its symptoms and their underly-
ing pathological mechanisms, which are still being uncovered, is
of vital importance.
Many possible treatments for different aspects and stages of
COVID-19 are being actively pursued. Evidence suggests that
remdesivir (DrugBank: DB14761), a broad-spectrum antiviral
medication, can shorten the time to recovery in adults hospital-
ized with COVID-19 infection and pneumonia (though the effect
is not statistically significant)4 and more recent evidence
suggests that dexamethasone (DrugBank:DB01234), a cortico-
steroid that suppresses inflammation, may reduce mortality in
patients with severe COVID-19.5 However, currently no treat-
ment is available to prevent progression of COVID-19 to severe
disease, and our knowledge of the causes and optimal medical
management of the symptoms and resulting clinical complica-
tions of COVID-19 are limited.
A large amount of biomedical andmolecular data are available
to aid the massive research effort to address the COVID-19
pandemic. Before the pandemic began, there existed a large
amount of biomedical data for coronaviruses other than SARS-
CoV-2 (SARS-CoV and MERS-CoV6 as well as many other path-
ogenic and non-pathogenic coronaviruses), such as viral
genome and transcriptome sequences, viral/host gene interac-
tions, gene function, epidemiological data, and clinical case
data. Much of this information is now also available for SARS-
CoV-2. In addition, there is also a large amount of data about
drugs that may offer a treatment for COVID-19, as well as the
protein targets for each drug.
However, researchers are confronted with a number of tech-
nical challenges when trying to use existing data to discover
actionable knowledge about COVID-19. The data needed to
address a given question are typically isolated in different data-
bases and use different identifiers. These data sources are also
often stored in different formats, requiring transformation or pre-
processing in order to serve the task at hand. For example, to
examine the function of proteins targeted by Food and Drug
Administration (FDA)-approved antiviral drugs, one must down-
load and integrate drug, drug target, and FDA approval status
data from, for example, Drug Central in a custom-made TSV
format7 and functional annotations from, for example, Gene
Ontology in GPAD format.8 Furthermore, many datasets are up-
dated periodically, which requires researchers to re-download
and re-process data in order to perform their analysis on the
most current data.
To tackle the daunting challenge of bringing together these
disparate sources of information and extracting useful knowl-
edge from them, we used knowledge graphs (KGs). KGs are a
way to represent and integrate heterogeneous data and their in-
terrelationships. In a KG, discrete entities or pieces of informa-
tion form distinct nodes interconnected by edges, where both
nodes and edges are typed using a hierarchical system such
as an ontology.9
For example, nodes of type ‘‘protein’’ representing individual
entities (such as human ACE2 or SARS-CoV-2 Spike) can be in-
terconnected via edges of type ‘‘orthologous to’’ or ‘‘interacts
with,’’ and these nodes can be connected with other kinds of no-
des representing diseases, drugs, and so on. This kind of repre-
sentation is amenable to complex queries (e.g., ‘‘which drugs
target a host protein that interacts with a viral protein?’’), and
also to graph-based machine learning techniques.
Related Work
Therehavebeena fewparallel efforts toconstructKGs to integrate
COVID-19 data, each integrating different data sources and con-
structed for different purposes. Several efforts have constructed
KGs by ingesting and transforming scientific literature10 (https://
lg-covid-19-hotp.cs.duke.edu/), somewith a few additional types
of data also included, such as confirmed case and mortality data
(https://github.com/covidgraph/); clinical information, drug trial,
and sequencing data (https://www.wikidata.org/wiki/
Wikidata:WikiProject_COVID-19); drug, drug trial, and genome
sequence data (https://ds-covid19.res.ibm.com/); diseases,
chemicals, and genes.11 Other KG efforts ingest a wider array of
data, including diseases, genes, proteins and their structural
data, drugs, and drug side effects;12 pathways, proteins, genes,
drugs, diseases, anatomic terms, phenotypes, microbiome
(https://spoke.ucsf.edu/); genes, proteins, diseases, phenotypes,
genome sequences13 (https://knetminer.com/); and geographic,
viral genes, genes, and proteins (https://github.com/sbl-sdsc/
coronavirus-knowledge-graph). Several projects have focused
specifically on integrating a wide variety of COVID-19 data to
create KGs to investigate drug repurposing14,15,16 (https://
github.com/gnn4dr/DRKG). The effort described here is unique
in that it allows users to more flexibly remix specific data types
from specific data sources (by virtue of its use of the KGX tool), it
integrates more tightly with ontologies (Human Phenotype
Ontology [HPO],Mondo,andGeneOntology [GO]) andwithdown-
stream machine learning tools (i.e., Embiggen), it offers a more
detailed summary of the contents of its KG in a machine readable
format, it covers a wider range of input data sources, and it auto-
matically incorporates new and updated data.
Here, we present a comprehensive COVID-19 KG derived
from 13 knowledge sources and containing 377,482 nodes and
21,433,063 edges. The KG is freely available for download at
https://kg-hub.berkeleybop.io/kg-covid-19/, and the framework
to produce the KG is freely available at https://github.com/
Knowledge-Graph-Hub/kg-covid-19. The knowledge graph
was constructed using modern ontology best practices whereby
different data sourceswere normalized andmerged. KG-COVID-
19 allows flexible remixing of component subgraphs for users
interested in specific areas. We demonstrate several use cases
including graph-based machine learning.
RESULTS
The KG-COVID-19 Framework
We created KG-COVID-19 to address the challenge of inte-
grating data for COVID-19 response. KG-COVID-19 is a
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framework that enables the creation of customized KGs contain-
ing COVID-19 knowledge for different applications. For example,
a drug repurposing application would make use of protein data
linked with approved drugs, while a biomarker application could
use data on gene expression linked with pathways. The method-
ology is not limited to COVID-19, but could support data
integration for any biomedical research effort. In addition, KG-
COVID-19 was designed to use a wide variety of human and
non-human data resources in order to model important relation-
ships and processes underlying human disease mechanisms.
For example, in order to model host response factors in humans,
it is necessary to also include mechanisms of virology and
viral genes.
Constructing the Knowledge Graph
Our process for generating the KG was designed to support
interoperability, preserve provenance, and provide the ability to
flexibly mix andmatch data from different sources. The workflow
is divided into three steps: data download (fetch the input data),
transform (convert the input data to KGX interchange format),
and merge (combine all transformed sources) (Figure 1).
The download step retrieves data from multiple sources using
a YAML file that specifies the source URLs (Figure 1A). Our expe-
rience has shown that this step is a frequent point of failure in
many extract, transform, and load (ETL) pipelines and separating
out this step helps mitigate this issue.
The data sources we ingest are focused on our use case: drug
repurposing (e.g., drug and drug target data, protein interaction
data, ontologies important in disease, such as the HPO and the
Mondo disease ontology). However, we also ingest data sources
that our user community requests by opening tickets on our proj-
ect GitHub page (https://github.com/Knowledge-Graph-Hub/
kg-covid-19).
The transform step (Figure 1B) involves parsing the input files
and transforming them to a graph-based representation. We
have devised a simple yet expressive format called KGX inter-
change format:https://github.com/NCATS-Tangerine/kgx/blob/
master/data-preparation.md
a serialization (i.e., the process of converting an object into a
format, usually text, that can be re-created when needed) for
representing a graph that combines features of Resource
Description Framework (RDF) and property graphs (i.e., simpli-
fied graphical representations consisting of sets of nodes and
edges containing key-value pairs). KGX interchange format con-
sists of two tabular files, one for representing graph nodes and
their properties, the other for representing edges and their prop-
erties (Figure 2). The format itself is a specialized TSVwith certain
guidelines on how to represent nodes and edges in a graph.
Figure 1. The KG-COVID-19 Framework for Producing KGs
The framework is divided into three modular steps: download, transform, and merge.
(A) The download step retrieves all datasets needed for ingestion using a set of URLs specified in a YAML file.
(B) The transform step applies Python code that is specific to each source to transform the most useful elements of each source and emit a graph in TSV format.
(C) Themerge step uses a YAML file to read the user-specified datasets (among those produced in the transform step) andmerge them into a single KG. Different
YAML files can be constructed to mix and match different input data from B, but each merge operation yields a single merged graph. Both the transform and
merge steps rely heavily on KGX, a powerful tool for manipulating knowledge graphs (https://github.com/NCATS-Tangerine/kgx).
ll
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Using standards from the Semantic Web, nodes in the graph are
identified by Compact Uniform Resource Identifiers (CURIEs).17
These can be expanded to an Information Resource Identifier
(IRI), which is the global identifier for this node. All nodes are as-
signed a type using the ‘‘category’’ node property, and all edges
are typed using the ‘‘edge_label’’ property. Where possible, one
can use classes from the Biolink Model (https://biolink.github.io/
biolink-model), a high-level data model for representing biolog-
ical and biomedical knowledge. Granular typing of nodes is
possible by adding additional classes to the ‘‘category’’ prop-
erty. Granular typing of edges is possible by adding a more spe-
cific relation to the ‘‘relation’’ property. For example, one can use
a class from the Relation Ontology (RO) (https://github.com/
oborel/obo-relations) to further classify the semantics of
an edge.
The merge step (Figure 1C) combines the component data-
sets into a KG. The merging of two or more graphs is per-
formed by the KGX tool where nodes that have identical CU-
RIEs and edges that have the same source node, edge type,
and target node are merged together. When nodes and edges
from two different sources do have conflicting properties, we
ensure that the properties are preserved. For example, If two
nodes had conflicting values for the same property, then we
convert the type of the property to a list and keep track of
both the values where the order of the list signifies the direc-
tionality of the merge. This step is informed by a YAML file
that specifies what datasets should be included, to allow for
flexible remixing of subgraphs. In addition to selecting different
component datasets to be merged, the user can also filter no-
des and edges from each source by the node ‘‘category’’ and
‘‘edge_label,’’ allowing fine-grained control of the resulting
graph. By default, all nodes and edges from all component da-
tasets are merged. Optionally, the merged graph can be loaded
into any triple/RDF store or Neo4j database.
Figure 2. A Typical Transformation of Records from an Input File into Entries in a nodes.tsv and edges.tsv File Representing the Nodes and
Edge in a Graph
These nodes and the edge can be further transformed into RDF triples.
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Design Principles
While our framework offers flexibility in deciding how best to
transform each data source, KG-COVID-19 follows some gen-
eral design principles to maintain the quality of the resulting KG.
Ensure Reproducibility
Our framework is designed to allow users to easily reproduce the
KGs used in downstream analysis. The download and transform
steps save all ingested data and the transformed data locally after
running the pipeline to produce a KG. In addition, we provide pre-
built versions of our KG (https://kg-hub.berkeleybop.io/kg-covid-
19/). A new build is constructed each month, and also whenever
changes are made to the code in the KG-COVID-19 framework.
Each build contains the date the build was constructed, the exact
commands that were run to produce the KG, the input data that
was ingested, the transformed subgraphs for each source,
detailed statistics about the contents of the build, and the KG itself
in RDF, KGX TSV, and Blazegraph journal format.
Ensure Interoperability Through Standardized Node and
Edge Representations
We use a core set of standardized ontologies and the Biolink
Model (https://biolink.github.io/biolink-model), a biological data
model for categorizing nodes and edges, to facilitate interopera-
bility and data summarization. To ensure Biolink Model compli-
ance, a Biolink category and a Biolink predicate are required
for the categorization of nodes and edges, respectively. Since
Biolink predicates are typically very broad in scope, the edge
can be further categorized by adding amore specific description
in the ‘‘relation’’ property using a term from the RO.18 Categori-
zation using ontologies and the Biolink Model provides a conve-
nient way to assess what types of data have been ingested from
each source, record provenance information, and also facilitates
interoperability with other transformed datasets.
Ingest Only Relevant Data
Only the subset of features in each dataset that are likely to be
useful for downstream applications are preserved, and only state-
ments for authoritative or trusted sources are ingested (for
example, assertions about protein interactions are not ingested
from a drug database, a trusted resource like the IntAct Molecular
Interaction Database would be preferred for protein interactions).
Normalize Identifiers at the Time of Ingest
Identifier (ID) normalization is crucial for ensuring connectedness
and the utility of the graph.
We refer to the Biolink Model to provide the preferential order
of identifier prefixes to be used for a particular Biolink class. For
example, in the case of Gene class (https://biolink.github.io/
biolink-model/docs/Gene), the model prescribes HUGO Gene
Nomenclature Committee (HGNC), NCBIGene, ENSEMBL,
where the order of prefixes matters: identifiers from HGNC
namespace are given a higher priority than NCBIGene and EN-
SEMBL. In the case of Protein class, the model prescribes Uni-
ProtKB identifiers. For drugs and other chemical compounds,
the model recommends the following: CHEBI, CHEMBL, Drug-
Bank, PubChem. Identifiers can also be normalized by adding
cross-references to other identifiers in the ‘‘xrefs’’ property of no-
des, which is the ‘‘xrefs’’ column in the KGX interchange format
TSV describing the nodes.
Preserve Provenance
Each ingest adds a ‘‘provided_by’’ column in the edge TSV file,
which ensures that graphs into which the data are merged (Fig-
ure 1C) contain a record of which ingest produced each edge.
The preservation of all files used to generate the graph in the
download step (Figure 1A) makes it possible to trace each
node and edge to the entries in the input file that generated
them. PubMed IDs are added to the ‘‘publication’’ column, where
available, to provide additional provenance.
Downstream Tooling for Querying and Machine
Learning
The KG-COVID-19 framework contains tooling for common
graph operations. The framework can create training and test
datasets in graph form for machine learning applications such
as training classifiers or regressors for link prediction (see Exper-
imental Procedures). It also includes a query function that can
execute prewritten or custom SPARQL queries on a given
SPARQL endpoint (by default, our endpoint: http://kg-hub-rdf.
berkeleybop.io/blazegraph/#query).
Current Contents of KG-COVID-19
A schematic diagram of all data sources currently ingested is
shown in Figure 3. The Sankey plot in Figure 3 provides insight
into the distribution of node and edge types and the connections
between nodes in a KG, which is useful for verifying the accuracy
of a KG build. The data we ingest are focused on sources rele-
vant to drug repurposing for our downstream querying and ma-
chine learning applications, prioritizing drug databases, protein
interaction databases, protein function annotations, COVID-19
literature, and related ontologies. The KG contains drug and
chemical compound data from several databases, currently
DrugCentral,19 the Pharmacogenomics Knowledgebase
(PharmGKB),20 Therapeutic Target Database (TTD),21 and
ChEMBL;22 functional annotations and synonyms for coronavi-
rus genes and proteins from the GO; and protein interaction
data from STRING23 and the IntAct Molecular Interaction Data-
base.24 The IntAct protein interaction dataset contains coronavi-
rus-human protein interaction data taken from 152 COVID-19
publications. We ingest data about COVID-19 scientific publica-
tions to identify instances of concepts such as GO terms, Uni-
Prot Knowledgebase (UniProtKB) proteins, National Center for
Biotechnology Information (NCBI) and HGNC genes, and
ChEMBL IDs via SciBite annotations (https://github.com/
SciBiteLabs/CORD19) of the COVID-19 Open Research Dataset
(CORD-19).25 To capture ontology-based annotations, the rela-
tional graphs for the GO,8 HPO,26 and Mondo Disease
Ontology27 are ingested, and annotations are added to the graph
as provided by each ingest (https://github.com/Knowledge-
Graph-Hub/kg-covid-19/wiki). In addition, we ingest GO Causal
Activity Models (GO-CAM) models that capture biological sys-
tems such as protein pathways, including those important in
SARS-CoV-2 infection.28
Use Cases
While we designed KG-COVID-19 to allow flexible reuse and re-
mixing of data to produce custom KGs, our immediate use case
is to provide a COVID-19 KG that can be used for machine
learning to produce actionable knowledge about COVID-19 (Fig-
ure 4). This use case demonstrates several features of KG-
COVID-19, namely: normalization and merging of disparate
data sources with different namespaces and formats, flexible
ll
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remixing of component subgraphs, and a regular update cycle to
keep up with new knowledge. We follow the workflow described
in Figure 1 to produce the KG-COVID-19 KG. From the final
merged graph, KG-COVID-19 produces training and test data-
sets suitable formachine learning applications (see Experimental
Procedures). Embiggen (unpublished data), our implementation
of node2vec and related machine learning algorithms, is applied
to this KG to generate embeddings, vectors in a low dimensional
space which capture the relationships in the KG. Embiggen is
trained iteratively to identify optimal node2vec hyperparameters
(walk length, number of walks, p, q , and so forth) and to then
train classifiers (e.g., logistic regression, random forest, support
vector machines) that can be used for link prediction. The trained
classifiers can then be applied to produce actionable knowl-
edge: drug to disease links, drug to gene links, and drug to pro-
tein links. The latter would indicate a drug that might be useful for
COVID-19 treatment.
To demonstrate the usefulness of KG-COVID-19 for machine
learning applications, we created embeddings for nodes and
edges from the KG-COVID-19 KG and visualized the embeddings
in two dimensions using a t-SNE plot (Figure 6). While only the
graph structure and no biological typing of nodes was used to
generate the embeddings, the nodes of the same type appear to
be located closer to each other when projected into latent space
than nodes of differing biological types (i.e., genes are closer to
other genes than they are to drugs) a phenomenon that is often
observed inhierarchically structureddata29anda feature forwhich
t-SNEs are known.30 This indicates that the embeddings encode
biological information that can be used for machine learning.
While the initial development of KG-COVID-19 has focused on
our machine learning applications, other use cases have
emerged. As part of the National Virtual Biotechnology Labora-
tory (NVBL), we have found it useful to perform hypothesis-
based querying of the KG to identify viral and human proteins
that make attractive drug targets.31 For example, we have
queried the KG to retrieve from our KG host proteins that are
known to interact with viral proteins, and these are further filtered
according to whether these host proteins are targets of
approved drugs (Figure 5). These data are further analyzed
with downstream analyses to assess their suitability for drug re-
purposing. Our KG is also part of a federated query used by the
NVBL to collate and share up-to-date information related to
COVID-19 and SARS-CoV-2. In addition, the National COVID
Cohort Collaborative (N3C) has incorporated our KG as an
Figure 3. Schematic Representation of the Data Currently Ingested into the KG-COVID-19 Knowledge Graph
(Top) Polygons shown correspond to the various data sources currently ingested into the KG, and the small colored circles indicate the data types ingested from
this source. (Bottom) Sankey plot showing the Biolink categories for edges in the KG-COVID-19 graph. Left and middle columns show Biolink categories for
edges, right column indicates the source of the data from which the edges were derived. Line widths are proportional to the number of edges.
Figure 4. Workflow for Machine Learning Application of KG-COVID-19 Knowledge Graph
(A) In order to train classifiers for use in link prediction, training and test graphs are first produced from the original KG-COVID-19 graph (see Experimental
Procedures). These graphs are used by Embiggen to generate random walks, embeddings, and finally a classifier. The test graphs are used to assess the
performance of the classifier. This step is performed iteratively in order to identify optimal hyperparameters.
(B) The classifiers are applied to the KG-COVID-19 to perform link prediction in order to identify links that correspond to actionable knowledge: for example, links
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ontologically informed way to combine their clinical datasets (by
virtue of our integration with GO, HPO, and Mondo). The N3C
also uses our KG to incorporate all of our transformed and
harmonized data, saving them the onerous task of collecting
and integrating all of those data sources individually.
DISCUSSION
A ‘‘KG-hub’’ Pattern for Data Sharing
The idea behind a KG-Hub is to provide a platform for building
and exchanging knowledge graphs by following a set of guide-
lines and design principles (https://knowledge-graph-hub.
github.io/) that facilitates interoperability and reproducibility.
The goal of a KG-Hub is to serve as a collective resource to
simplify the process of generating biological and biomedical
KGs and thus reducing the barrier for entry to new participants.
It also serves as a central resource to enable discovery and ex-
change of KGs. KG-Hub is designed to be an open-source com-
munity-supported resource. We are committed to maintaining
this resource and welcome new national and international
collaborations to help support this work. Our KG-COVID-19
framework adopts KG-Hub design principles and thus can be
considered as the first instance of KG-Hub.
ID Normalization Challenges for SARS-CoV-2 Entities
Since the usefulness of a KG depends on its connectedness, ID
normalization is crucial. Normalization of IDs for SARS-CoV-2
entities in particular is challenging, for several reasons. First,
SARS-CoV-2 produces identical cleavage products from
different polyproteins, and UniProt assigns a different ID to
each of these identical cleavage products. For example, UniProt
uses PRO_0000338259 to identify the cleavage product nsp5,
the 3C-like protease, if it is cleaved from replicase polyprotein
1a, and PRO_0000449623 if it is cleaved from replicase polypro-
tein 1ab. Protein Ontology, in contrast, uses PR_000050274, ir-
respective of the polyprotein from which it was cleaved. Note
that the UniProt ‘‘PRO_’’ prefix is unrelated to the Protein
Ontology namespace. For our KG, it is crucial that identical pro-
teins be represented with a single node such that other informa-
tion can be efficiently linked to them. We arbitrarily chose
PRO_0000449623 as the ID to represent this cleavage product,
and all other IDs for this cleavage product are stored as cross-
references for this node in our KG. Second, each cleavage prod-
uct can have a large number of synonyms. For example, nsp5
has at least 40 synonyms that are used in the literature (e.g.,
3CL-PRO, 3CLp, Mpro, 3C-like proteinase). Furthermore,
some synonyms (e.g., ‘‘S’’ for spike protein) are difficult to
recognize when applying NLP to SARS-CoV-2 literature, which
represents a further challenge for computationally identifying
the occurrences of such entities in text. We have compiled our
canonical IDs, synonyms, and cross-references for each
SARS-CoV-2 protein and cleavage product in our KG in a pub-




KGs provide a way of integrating heterogeneous data from
different sources and combining different data modalities.
KG-COVID-19 generates a KG for COVID-19 focused around
molecular and chemical information, enabling users to
conduct complex queries over relevant biological entities as
well as machine learning analyses to generate graph embed-
dings for making predictions. The lightweight framework we
have developed provides a rapid route for bringing together
new sources of data and knowledge, including KGs from
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Materials Availability
This study did not generate any physical material.
Figure 5. Hypothesis-Based Querying of KG-COVID-19 Knowledge Graph for Using SPARQL Queries
(Top) An SPARQL query retrieves approved drugs that target human proteins that physically interact with SARS-CoV-2 protein. (Bottom) An SPARQL query
retrieves approved drugs that target human proteins that physically interact indirectly with SARS-CoV-2 through another human protein. The suitability of these
drugs for repositioning are evaluated by NVBL collaborators, for example by analyzing available structural data to support repositioning.
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Data and Code Availability
The Python code for KG-COVID-19 is available from the project wiki: https://
github.com/Knowledge-Graph-Hub/kg-covid-19/wiki.https://github.com/
Knowledge-Graph-Hub/kg-covid-19/wiki
The Python code is distributed under a BSD3 license.
The KG-COVID-19 KG containing all data sources (in RDF and TSV format) is
freely available at: https://kg-hub.berkeleybop.io/kg-covid-19/
An SPARQL endpoint is here:http://kg-hub-rdf.berkeleybop.io/blazegraph/
#query.
KG Generation Pipeline
The framework to produce our KG is essentially an ETL system with additional
tooling to facilitate downstream uses (e.g., to produce subgraphs for machine
learning training, run SPARQL queries). To ensure that the code remains func-
tional and to detect breaking changes in data from upstream sources, we run
our pipeline and unit tests regularly using a continuous integration system
(https://www.jenkins.io/). This pipeline emits a KG that integrates all available
data sources, in both TSV and RDF format, and also loads this KG into a Blaze-
graph database. A YAML file containing an inventory of the Biolink categories
andBiolink associations of all data in the KG is also produced during themerge
step (Figure 1). On a commodity server with 200 GB of memory, generation of
the KG containing all source data requires a total of 3.7 h (0.13 h, 1.5 h, and
2.1 h for the download, transform, and merge step, respectively), with a
peak memory usage of 34.4 GB and disk use of 37 GB.
Generation of Training and Test Edges for Machine Learning
Applications
To generate positive edges, a set of positive test edges equal in number to [(1 -
train_fraction) * number of edges in input graph] is selected from the edges in
the input graph, where train_fraction is a number between 0 and 1 indicating
the fraction of the graph to use for training. Positive test edges are selected
such that removing them from the graph would not break it into disjoint com-
ponents. These positive edges are removed from the edges of the input graph
and are then emitted as the training edges. A set of negative edges is con-
structed by randomly selecting pairs of nodes that are not connected by an
edge in the input graph. The number of negative edges emitted is equal to
the number of positive edges emitted above. If the user requests a validation
set, the positive test edges are divided equally to yield positive test and valida-
tion sets, and negative test edges are divided equally to yield negative test and
validation sets.
Embeddings and t-SNE Plot for Knowledge Graph Visualization
Wegenerated embeddings from our KG using Embiggen, our Python library for
graph embedding and machine learning, using node2vec with a skip-gram
model, 128 embedding dimensions, and parameters p and q of 1 (which are
typically used default parameters for node2vec).32 Embiggen is freely available
at https://github.com/monarch-initiative/embiggen. These embeddings were
used to generate a t-SNE plot that represents the embeddings for each
node in two-dimensional space, using MulticoreTSNE (https://github.com/
DmitryUlyanov/Multicore-TSNE) (Figure 6).
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.
patter.2020.100155.
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Mungall, C., Neuhaus, F., Rector, A.L., and Rosse, C. (2005). Relations
in biomedical ontologies. Genome Biol. 6, R46.
19. Ursu, O., Holmes, J., Knockel, J., Bologa, C.G., Yang, J.J., Mathias, S.L.,
Nelson, S.J., and Oprea, T.I. (2017). DrugCentral: online drug compen-
dium. Nucleic Acids Res. 45, D932–D939.
20. Thorn, C.F., Klein, T.E., and Altman, R.B. (2013). PharmGKB: the
Pharmacogenomics knowledge base. Methods Mol. Biol. 1015, 311–320.
21. Chen, X., Ji, Z.L., and Chen, Y.Z. (2002). TTD: therapeutic target database.
Nucleic Acids Res. 30, 412–415.
22. Gaulton, A., Bellis, L.J., Bento, A.P., Chambers, J., Davies, M., Hersey, A.,
Light, Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B., et al. (2012).
ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic
Acids Res. 40, D1100–D1107.
23. Szklarczyk, D., Gable, A.L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas,
J., Simonovic, M., Doncheva, N.T., Morris, J.H., Bork, P., et al. (2019).
STRING v11: protein-protein association networks with increased
coverage, supporting functional discovery in genome-wide experimental
datasets. Nucleic Acids Res. 47, D607–D613.
24. Orchard, S., Ammari, M., Aranda, B., Breuza, L., Briganti, L., Broackes-
Carter, F., Campbell, N.H., Chavali, G., Chen, C., del-Toro, N., et al.
(2014). The MIntAct project–IntAct as a common curation platform for 11
molecular interaction databases. Nucleic Acids Res. 42, D358–D363.
25. Kohlmeier, S., Lo, K., Wang, L.L., and Yang, J.J. (2020). COVID-19 Open
Research Dataset (CORD-19) (Zenodo).
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Supplement Table 1. ​Summary of data sources currently ingested by KG-COVID-19. For each 
source, version/date information for the currently ingested data is also shown. An up-to-date list 
of URLs from which the data can be downloaded is available at: 
https://github.com/Knowledge-Graph-Hub/kg-covid-19/blob/master/download.yaml 
